Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile

Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile

Abstract Background Targeting CD47/SIRPα axis has emerged as a promising strategy in cancer immunotherapy. Despite the encouraging clinical efficacy observed in hematologic malignancies through CD47-SIRPα blockade, there are safety concerns related to the binding of anti-CD47 antibodies to CD47 on t...

Full description

Bibliographic Details
Main Authors: Tao Wang, Si-Qin Wang, Yin-Xiao Du, Dan-Dan Sun, Chang Liu, Shuang Liu, Ying-Ying Sun, Hai-Long Wang, Chun-Sheng Zhang, Hai-Long Liu, Lei Jin, Xiao-Ping Chen
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Translational Medicine
Subjects:
Cancer immunotherapy
CD47
Pyroglutamic acid
Phagocytosis
Online Access:https://doi.org/10.1186/s12967-023-04710-6

Internet

https://doi.org/10.1186/s12967-023-04710-6

Similar Items